100 likes | 119 Views
3 rd International ELN Workshop: Standardization of Flow Cytometry in MDS London, Greenwich 4-6 November 2010 a.a. van de loosdrecht, chair r. ireland, co-chair update ELNet wp8; ASH Orlando, December 4, 2010 and ELNet WP conference, Mannheim, February 1, 2011.
E N D
3rd International ELN Workshop:Standardization of Flow Cytometry in MDSLondon, Greenwich 4-6 November 2010a.a. van de loosdrecht, chairr. ireland, co-chairupdate ELNet wp8; ASH Orlando, December 4, 2010and ELNet WP conference, Mannheim, February 1, 2011
3rd International ELN Workshop:Standardization of Flow Cytometry in MDSLondon, Greenwich 4-6 November 2010a.a. van de loosdrecht, chairr. ireland, co-chair • 12 countries; 28 participants; in- and outside Europe • Austria: P. Valent • France: MC Bene, J. Feuillard • Germany: W. Kern • Great Britain: R. Ireland, U. Johansson, M. Cullen, G. Mufti, T. Minle, S. Kordasti • Italy: M. della Porta [absent] • Netherlands: C. Alhan, A.A. van de Loosdrecht, J te Marvelde, V. van de Velden, TM Westers, B. Moshaver, T deWitte • Spain: [absent] • Sweden: A. Porwit • Greece: K. Psarra • Japan: K. Ogata • USA: D. Wells, M. Loken, J Cutler • Australia: K. Burbury
Goal: • define minimal flow cytometric criteria to analyse MDS • ELN 2011 [2 consensus documents: rationale/technical] • Define: role of FCM: • Diagnosis • Prognosis • predictive value for R/ [emerging new drugs] • disease monitoring
Proposed antigens of importance in FCM in MDS: ELN consensus 2009 ELN consensus document MDS and flow cytometry: van de Loosdrecht, ELN members WP8, et al., Haematologica 2009;94:1124-1134
Overview of some recommended flow cytometric analyses of subsets in the BM by the ELNet; London 2010
Analysis of a minimized multiparameter panel % CD34+ myeloblasts % CD34+ B cells of total CD34+ CD45 expression of Ly vs. Myeloblasts SSC ratio of CD10- neutrophils vs. Ly Ogata et al, Blood, 2006; Ogata/Della Porta, Haematologica, 2009 Della Porta, et al., 2011 (to be submitted); Japan/Italy/Netherlands/Sweden/USA/UK
Analysis of myelomonopoiesis April 1, 2010 severe mild normal n=45 n=22 n=58 n=24 n=45 n=34 n=31 n=37 Wells et al., Blood, 2003; Van de Loosdrecht and Westers et al., Blood, 2008 Alhan et al.; unpublished data set june 2010 Chu et al., personal communication ASH2010; Kern et al., Cancer 2010
FCSS is related to transfusion-dependency and progression to AMLlow/int-I risk MDS myeloblasts either: CD5 (o), CD7 (o) or CD56 (o) positive In part published: Loosdrecht AA van de, Westers TM et al., Blood 2008;111 Chu et al., personal communication; ASH#2010
Clinical impact of flow cytometry in MDS 1. Flow cytometry is recognized in the diagnostic and prognostic work-up of patients with cytopenia (ELN-2009; ELN-2011) 2. An ELN consensus guideline for flow cytometry in MDS is now available (ELN, Haematologica, 2009; updated 2011; to be submitted) 3. Rationale for clinical use of flow cytometry is defined (ELN-2011: to be submitted)
Perspectives: 2011 • Submission 1q/2011: 3 ELN consensus documents • 4th international ELN meeting in Pavia Italy: co-chair Matteo dellaPorta (October 2011) • diagnostics • FCSS-revised • erythroid-lineage • incorporate software tools for analysis/statistics • clinical reporting